In response to heightened tensions after a recent terror attack in Pahalgam, India’s Department of Pharmaceuticals has initiated a detailed review of pharmaceutical exports to Pakistan. The government has asked the Pharmaceuticals Export Promotion Council of India (Pharmexcil) to provide data on exports over the past two years.

India exported approximately $208 million worth of pharmaceutical products to Pakistan until March 2025. Now, with the Attari border checkpoint closed a vital trade route a complete trade embargo is being considered.

Sources indicate that Pharmexcil has already submitted the requested data to the Department of Pharmaceuticals (DoP). Officials suggest a final decision could soon impact all pharmaceutical categories, including APIs (active pharmaceutical ingredients), bulk drugs, vaccines, and finished formulations.

This potential ban aligns with India’s broader strategy to tighten trade relations with Pakistan after repeated security threats. Industry experts warn the move may disrupt Pakistan’s pharmaceutical supply chain significantly, while Indian exporters prepare for market diversifications.

The Indian pharmaceutical sector, one of the world’s largest suppliers, is likely to face short-term adjustments, though overall global exports remain strong.

For the latest updates on India-Pakistan trade relations and their economic impact, stay tuned.